The Psychopharmacology Institute Podcast

Educational Psychopharmacology Podcasts

Visit us at psychopharmacologyinstitute.com/ where you can find more podcasts and some lectures absolutely free

You can also become a Silver or Gold member to get full access, and earn up to 155 CMEs , including 40 SAs.

Get Instant Access

Top 10 Drug Combinations in Major Depressive Disorder: Interview with Dr. Michael Thase PART 2

Transcript Hi! You’re listening to the Psychopharmacology Institute podcast. I’m your host, Dr. Wegdan Rashad and this is the show that aims to help you, the mental health clinician stay sharp on psychopharm! Today we are continuing our discussion from the last episode on the top 10 drug combinations in the management of major depressiveRead More

  • Top 10 Drug Combinations in Major Depressive Disorder: Interview with Dr. Michael Thase PART 2

  • Top 10 Drug Combinations in Major Depressive Disorder: Interview with Dr. Michael Thase PART 1

  • Reducing Suicidal Ideation Through Insomnia Treatment: A Randomized Clinical Trial

  • The Clinician’s Algorithm To Managing COVID-19 Related Delirium

  • Does Samidorphan Reduce Olanzapine-Induced Weight Gain?

  • Managing Depression, Anxiety, and Psychosis in Parkinson’s Disease

  • Management of Psychiatric Disturbances in Parkinson’s Disease and Other Hypokinetic Movement Disorders

  • Case Discussion: Managing Agitation in Autism Spectrum Disorder

  • Pharmacotherapy of Autism Spectrum Disorder: Randomized BAART Clinical Trial

  • Antidepressant Safety During Pregnancy: Autism, IQ and Teratogenicity

  • Does Prenatal Stress Predispose to Borderline Personality Disorder?

  • Clinical Pearls in Perinatal Psychiatry

  • What Do You Know About Cognitive Enhancers in Depression?

  • Can Lithium Prevent Dementia?

  • Psychopharm in 2019: Your Ultimate Guide

  • Clinical Storytime with Dr. Ken Gillman

  • Do Antidepressants Increase Risk of Dementia?

  • Behind the Scenes: Meet Our Team

  • “New” Antidepressants? A Quick Takes Episode

  • Why Don’t We Prescribe MAOIs?

  • Ketamine for Suicidal Ideation: A Quick Take Episode

  • The Basic Guide To Ketamine and Esketamine

  • Your Psych Guide to Pharmacogenetic Testing

  • Do You Order Pharmacogenetic Testing For Your Patients?

  • Transdermal Patches in Psychiatry: Interview with Dr. Leslie Citrome

  • MOC Self Assessment #9: Ketamine in Clinical Practice: State of The Art Update, Cardiac Side Effects of Psychotropic Drugs and Pharmacogenetic Testing in Psychiatry

  • Clinical Guide to Synthetic Opioids and Bath Salts

  • Designer Drugs: Can You Handle Spice?

  • What You Need To Know About Psychedelics

  • The Magic of the Serotonin Receptors

  • Generalized Anxiety Disorder: What if You Can’t Use An SSRI?

  • Approaching A Case of Generalized Anxiety Disorder: The Basics

  • How Helpful are Antipsychotic Plasma Levels?

  • How to Prescribe Natural Medications? Part 2

  • How to Prescribe Natural Medications? Part 1

  • How to Manage Adverse Effects of Clozapine – Part 2

  • How to Manage Adverse Effects of Clozapine – Part 1

  • Do SSRIs Increase Bleeding Risk?

  • Your Guide to Treating PTSD Comorbidities

  • How to Treat PTSD-Related Sleep Disturbances?

  • Prescribing Psychotropics in the Medically Ill

  • Psychotropics and Gastrointestinal Conditions: Prescribe with the Gut in Mind

  • Clinical Pearls in Geriatric Psychopharmacology

  • Treatment-Resistant Depression: Clinical Conundrum

  • How to Manage an Agitated Patient?

  • When to Discontinue Antipsychotics? Reviewing the Evidence

  • Are Drug Interaction Warnings Influenced by Drug Company Promotion? An Interview with Dr. Jeffrey Mattes

  • Do Depression Efficacy Trials Apply to Your Clinical Practice? An Interview with Dr. Mark Zimmerman

  • Psilocybin for Treatment-Resistant Depression: An Interview with Dr. Robin Carhart-Harris

Receive psychopharmacology updates in your inbox

Download the episodes or get the transcript and PDF version from our website:

Prescribing Tricyclic Antidepressants Safely: Drug Interactions, Side Effects, and Overdose

0.50 CMEs
This guide addresses tricyclic antidepressant safety across the prescribing lifecycle: CYP2D6 inhibitor interactions (fluoxetine, paroxetine, bupropion), CPIC-guided dosing in poor and ultrarapid metabolizers, a structured monitoring framework, agent selection across pregnancy, breastfeeding, and older adults, and overdose recognition.
Sebastián Malleza, M.D.
Psychopharmacology Institute
View more info

Ketamine and Esketamine: State of The Art – Interview

0.50 CMEs
A discussion with on ketamine and esketamine for treatment-resistant depression, covering regulatory differences, patient selection, placement in the treatment algorithm, maintenance and tapering, managing dissociative and dysphoric reactions, nausea, clinic workflow, bipolar and geriatric populations, and choosing between IV ketamine and esketamine.
Samuel Wilkinson, M.D.
Yale University School of Medicine
32.13 minutes of audio interview

Tricyclic Antidepressants in Psychiatry: Selection and Prescribing

0.50 CMEs
This guide examines tricyclic antidepressants as second- or third-line agents, covering the tertiary vs. secondary amine distinction and its implications for tolerability, a clinical decision framework for agent selection, AGNP-guided therapeutic drug monitoring with reference ranges for all six commonly used agents, dosing and titration strategies, and switching protocols.
Sebastián Malleza, M.D.
Psychopharmacology Institute
View more info

Management of Psychotropic-Induced Sexual Dysfunction

1.0 CMEs
A review of sexual dysfunction related to psychotropic medications, covering neurobiological mechanisms, prevalence across antidepressant and antipsychotic classes, and genetic risk factors. Practical guidance includes validated assessment tools, medication substitution strategies, off-label antidotes, and approaches to address modifiable contributors.
Anita H. Clayton, M.D., D.L.F.A.P.A., I.F.
University of Virginia School of Medicine, Charlottesville, VA
62.33 minutes in 10 sections

Quick Take Vol. 85

0.50 CMEs
Does Cobenfy maintain its efficacy and safety after one year of use? Should we reconsider trazodone for depression-associated insomnia despite AASM guidelines? Is antidepressant monotherapy in bipolar I as risky as previously thought? Does inflammation explain treatment resistance in older depressed adults? What risk factors predict stimulant misuse and diversion in ADHD patients?
Faculty: Scott R. Beach, M.D., Oliver Freudenreich, M.D., David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M., James Phelps, M.D., Paul Zarkowski, M.D.
33.5 minutes in 5 audio sections

Q1 2026 in Review: Milsaperidone, GLP-1 RAs, and Zuranolone

0.50 CMEs
Why did the FDA approve milsaperidone if it offers no clinical advantage over iloperidone? What does the FDA’s removal of the GLP-1 suicidality warning mean for your practice? How does ACOG’s updated guidance position zuranolone for severe postpartum depression?
Flavio Guzmán, M.D., M.D.
Psychopharmacology Institute
View more info

Use of Long-Acting Injectable Antipsychotics in Schizophrenia – Interview

0.50 CMEs
A discussion on long-acting injectable antipsychotics in schizophrenia, covering collaborative decision making, patient engagement strategies, LAI selection, dosing and switching considerations, injection site management, use in pregnancy, and emerging pipeline agents for expanding treatment options.
Brian Miller, M.D., Ph.D., M.P.H.
Medical College of Georgia Augusta University
34.06 minutes of audio interview

Addiction Psychopharmacology in Patients with Medical Comorbidities

1.25 CMEs
A practical guide to adjusting addiction pharmacotherapy in patients with significant medical comorbidities. Dr. Sevarino provides evidence-based dosing modifications for naltrexone, buprenorphine, methadone, and disulfiram across liver disease, renal impairment, cardiovascular disease, respiratory conditions, and infectious comorbidities, with integrated care frameworks for complex cases.
Kevin A. Sevarino, M.D.C.M., Ph.D.
Yale School of Medicine
72.5 minutes in 10 sections

Gastrointestinal Side Effects of Antidepressants: Mechanisms, Comparison and Management Strategies

0.50 CMEs
Sebastián Malleza, M.D.
Psychopharmacology Institute
View more info

Quick Take Vol. 84

0.75 CMEs
When should you taper a benzodiazepine, and how slowly? Does semaglutide reverse metabolic risk in schizophrenia patients on clozapine or olanzapine? Is EPA effective for TRD? Can brief psychotherapy enable safe antidepressant discontinuation? Is a ketogenic diet effective for depression and other psychiatric conditions?
Faculty: Scott R. Beach, M.D., Oliver Freudenreich, M.D., Derick E. Vergne, M.D., Paul Zarkowski, M.D., James Phelps, M.D.
47.02 minutes in 5 audio sections

Buspirone Guide: Pharmacology, Indications, Dosing Guidelines and Adverse Effects

0.50 CMEs
This guide provides a comprehensive overview of buspirone, a 5-HT1A partial agonist approved for generalized anxiety disorder, covering its non-GABAergic mechanism, pharmacokinetics, significant CYP3A4 drug interactions, dosing strategies, side effects, various special population considerations, and clinical positioning as a non-sedating anxiolytic without significant dependence risk.
Sebastián Malleza, M.D.
Psychopharmacology Institute
View more info

Managing Catatonia: From Clinical Assessment to Effective Intervention – Interview

0.50 CMEs
A discussion on catatonia assessment and management, covering diagnostic approaches including the Bush-Francis scale, differentiating catatonia from psychosis and deception, lorazepam challenge protocols, treatment strategies including benzodiazepines and ECT, and relapse prevention.
Scott R. Beach, M.D.
Harvard Medical School – Massachusetts General Hospital
30.15 minutes of audio interview
1 …